These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
31. Inhibitors of angiogenesis and cancer-related receptor tyrosine kinases. Mazitschek R; Giannis A Curr Opin Chem Biol; 2004 Aug; 8(4):432-41. PubMed ID: 15288254 [TBL] [Abstract][Full Text] [Related]
32. [Milestones leading to new perspectives in melanoma therapy]. Gilde K Magy Onkol; 2003; 47(1):3-11. PubMed ID: 12704449 [TBL] [Abstract][Full Text] [Related]
33. Current immunotherapeutic strategies in renal cell carcinoma. Amato RJ Surg Oncol Clin N Am; 2007 Oct; 16(4):975-86, xi-xii. PubMed ID: 18022554 [TBL] [Abstract][Full Text] [Related]
34. [Melanoma: a new therapeutic era]. Berthod G; Homicsko K; Bouchaab H; Matter M; Cerottini JP; Guggisberg D; Speiser D; Leyvraz S; Michielin O Rev Med Suisse; 2011 May; 7(296):1126-30. PubMed ID: 21721201 [TBL] [Abstract][Full Text] [Related]
35. Molecular markers of response to treatment for melanoma. Sznol M Cancer J; 2011; 17(2):127-33. PubMed ID: 21427556 [TBL] [Abstract][Full Text] [Related]
37. [Immunotherapy of malignant melanoma--basic principles and novel therapeutic approaches]. Enk AH; Becker JC; Schuler G J Dtsch Dermatol Ges; 2006 Aug; 4(8):635-45. PubMed ID: 16895565 [TBL] [Abstract][Full Text] [Related]
38. Target-based therapies in breast cancer: current status and future perspectives. Normanno N; Morabito A; De Luca A; Piccirillo MC; Gallo M; Maiello MR; Perrone F Endocr Relat Cancer; 2009 Sep; 16(3):675-702. PubMed ID: 19525314 [TBL] [Abstract][Full Text] [Related]